Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Fig. 4

Validation of HLA-DRA expression and its correlation with PD-L1. A Schematic protocol of validation on the NSCLC TMA cohort. B Representative images revealing HLA-DRA expression in para-tumor and tumor tissues in NSCLC. Magnification, 200×. C Expression levels of HLA-DRA in tumor and para-tumor tissues. D Representative images revealing PD-L1 expression in the high and low HLA-DRA groups. Magnification, 200×. E Differences in PD-L1 expression between the high and low HLA-DRA groups. F Correlation between HLA-DRA and PD-L1 expression in the NSCLC TMA cohort

Back to article page